Mitigating risk in academic preclinical drug discovery.

Paradigms and Technologies

Abstract

The number of academic drug discovery centres has grown considerably in recent years, providing new opportunities to couple the curiosity-driven research culture in academia with rigorous preclinical drug discovery practices used in industry. To fully realize the potential of these opportunities, it is important that academic researchers understand the risks inherent in preclinical drug discovery, and that translational research programmes are effectively organized and supported at an institutional level. In this article, we discuss strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology.

Authors

Dahlin, Jayme L; Inglese, James; Walters, Michael A;

Keywords

  • Academic Medical Centers/ economics
  • Academic Medical Centers/ standards
  • Academic Medical Centers/ trends
  • Animals
  • Cooperative Behavior
  • Drug Discovery/ economics
  • Drug Discovery/ standards
  • Drug Discovery/ trends
  • Drug Evaluation, Preclinical
  • Humans
  • National Institutes of Health (U.S.)
  • Risk
  • Small Molecule Libraries
  • Translational Medical Research/ standards
  • Translational Medical Research/ trends
  • United States

External Links